The fight against COVID19
23.81k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
Performance
| Watchlist | Change today | 1-month return | 1-year return | Total return |
|---|---|---|---|---|
| The fight against COVID19 | -0.42% | - | - | - |
| ^GSPC | -0.00% | -0.43% | +25.94% | +5478.14% |
14 symbols
| Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 148.95 | +0.23 | +0.15% | 4:00 pm GMT-4 | 7.09M | 7.61M | 358.47B |
| ABBV | AbbVie Inc. | 160.45 | -2.10 | -1.29% | 4:00 pm GMT-4 | 5.76M | 5.73M | 283.33B |
| PFE | Pfizer Inc. | 28.27 | +0.50 | +1.80% | 4:01 pm GMT-4 | 38.65M | 42.62M | 160.19B |
| SNY | Sanofi | 50.1 | +0.53 | +1.07% | 4:00 pm GMT-4 | 1.60M | 2.02M | 125.21B |
| REGN | Regeneron Pharmaceuticals, Inc. | 955.76 | -14.21 | -1.46% | 4:00 pm GMT-4 | 388.97k | 463.62k | 105.31B |
| GSK | GSK plc | 44.14 | -0.01 | -0.02% | 4:00 pm GMT-4 | 2.01M | 3.32M | 90.19B |
| GILD | Gilead Sciences, Inc. | 64.92 | -0.54 | -0.82% | 4:00 pm GMT-4 | 5.09M | 7.20M | 80.95B |
| MRNA | Moderna, Inc. | 121.89 | +0.82 | +0.68% | 4:00 pm GMT-4 | 2.50M | 3.88M | 46.71B |
| TAK | Takeda Pharmaceutical Company Limited | 13.06 | -0.22 | -1.66% | 4:00 pm GMT-4 | 1.56M | 1.65M | 41.09B |
| BNTX | BioNTech SE | 90.13 | -0.75 | -0.83% | 4:00 pm GMT-4 | 338.31k | 603.19k | 21.72B |
| VIR | Vir Biotechnology, Inc. | 9.54 | -0.39 | -3.93% | 4:00 pm GMT-4 | 986.85k | 1.05M | 1.30B |
| NVAX | Novavax, Inc. | 4.47 | -0.14 | -3.04% | 4:00 pm GMT-4 | 3.05M | 6.86M | 627.60M |
| INO | Inovio Pharmaceuticals, Inc. | 11 | -0.15 | -1.35% | 4:00 pm GMT-4 | 157.20k | 458.12k | 284.97M |
BenzingaSecond Death - Pfizer Reports Young Boy's Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trial
A young patient died due to cardiac arrest after receiving Pfizer Inc’s (NYSE:PFE) experimental gene therapy in a mid-stage trial for Duchenne muscular dystrophy (DMD), the company told in a letter to Parent Project Muscular Dystrophy. The boy was enrolled in Phase 2 DAYLIGHT study studying the treatment in boys at least two years old and under four years old. The patient received the investigational gene therapy, fordadistrogene movaparvovec (PF-06939926), in early 2023. Citing Pfizer, Reuters
Barrons.comTeva Stock Powers Ahead as Schizophrenia News Offsets Mixed Earnings
Shares of Teva Pharmaceutical Industries were climbing yet again on Wednesday, after the company announced positive results in a trial of a schizophrenia medicine. Its quarterly results, also disclosed early Wednesday, were mixed. Revenue was $3.8 billion for the quarter, slightly better than the FactSet consensus estimate of $3.7 billion, while non-GAAP diluted earnings were 48 cents a share.
Insider Monkey10 Future Dividend Kings in the Next 5 Years or Less
In this article, we discuss 10 future dividend kings in the next 5 years or less. You can skip our detailed analysis of the best dividend kings and the performance of dividend growth stocks, and go directly to read 5 Future Dividend Kings in the Next 5 Years or Less. Dividend Kings refer to a […]
